74 related articles for article (PubMed ID: 19249673)
1. Taking the stress out of melanoma.
Martin MJ; Carling D; Marais R
Cancer Cell; 2009 Mar; 15(3):163-4. PubMed ID: 19249673
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanoma.
McKee CS; Hill DS; Redfern CP; Armstrong JL; Lovat PE
Exp Dermatol; 2013 Nov; 22(11):767-9. PubMed ID: 24118207
[TBL] [Abstract][Full Text] [Related]
3. Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma.
Packer LM; East P; Reis-Filho JS; Marais R
Pigment Cell Melanoma Res; 2009 Dec; 22(6):785-98. PubMed ID: 19682280
[TBL] [Abstract][Full Text] [Related]
4. [Signal transduction in melanoma].
Yokoyama S
Seikagaku; 2013 Jun; 85(6):469-74. PubMed ID: 23875475
[No Abstract] [Full Text] [Related]
5. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
[TBL] [Abstract][Full Text] [Related]
6. Molecular drivers of cellular metabolic reprogramming in melanoma.
Abildgaard C; Guldberg P
Trends Mol Med; 2015 Mar; 21(3):164-71. PubMed ID: 25618774
[TBL] [Abstract][Full Text] [Related]
7. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
[TBL] [Abstract][Full Text] [Related]
8. BRAF in melanoma: current strategies and future directions.
Salama AK; Flaherty KT
Clin Cancer Res; 2013 Aug; 19(16):4326-34. PubMed ID: 23770823
[TBL] [Abstract][Full Text] [Related]
9. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells.
Sala E; Mologni L; Truffa S; Gaetano C; Bollag GE; Gambacorti-Passerini C
Mol Cancer Res; 2008 May; 6(5):751-9. PubMed ID: 18458053
[TBL] [Abstract][Full Text] [Related]
10. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation.
Wellbrock C; Marais R
J Cell Biol; 2005 Aug; 170(5):703-8. PubMed ID: 16129781
[TBL] [Abstract][Full Text] [Related]
11. The role of B-RAF in melanoma.
Gray-Schopfer VC; da Rocha Dias S; Marais R
Cancer Metastasis Rev; 2005 Jan; 24(1):165-83. PubMed ID: 15785879
[TBL] [Abstract][Full Text] [Related]
12. Regulation of ERK3/MAPK6 expression by BRAF.
Hoeflich KP; Eby MT; Forrest WF; Gray DC; Tien JY; Stern HM; Murray LJ; Davis DP; Modrusan Z; Seshagiri S
Int J Oncol; 2006 Oct; 29(4):839-49. PubMed ID: 16964379
[TBL] [Abstract][Full Text] [Related]
13. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Karreth FA; DeNicola GM; Winter SP; Tuveson DA
Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
[TBL] [Abstract][Full Text] [Related]
14. B-Raf(V600E) signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells.
Cui Y; Guadagno TM
Oncogene; 2008 May; 27(22):3122-33. PubMed ID: 18071315
[TBL] [Abstract][Full Text] [Related]
15. BRAF mutations in metastatic malignant melanoma: comparison of molecular analysis and immunohistochemical expression.
Ehsani L; Cohen C; Fisher KE; Siddiqui MT
Appl Immunohistochem Mol Morphol; 2014 Oct; 22(9):648-51. PubMed ID: 25046227
[TBL] [Abstract][Full Text] [Related]
16. Lack of correlation between IGFBP7 expression and BRAF mutational status in melanoma.
Schrama D; Kneitz H; Willmes C; Adam C; Houben R; Becker JC
J Invest Dermatol; 2010 Mar; 130(3):897-8. PubMed ID: 19829302
[No Abstract] [Full Text] [Related]
17. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
[TBL] [Abstract][Full Text] [Related]
18. Oncogenes in melanoma.
Polsky D; Cordon-Cardo C
Oncogene; 2003 May; 22(20):3087-91. PubMed ID: 12789285
[TBL] [Abstract][Full Text] [Related]
19. Protein phosphorylation goes negative.
Pawson T; Taylor L
Mol Cell; 2009 Apr; 34(2):139-40. PubMed ID: 19394291
[TBL] [Abstract][Full Text] [Related]
20. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling.
Dumaz N; Hayward R; Martin J; Ogilvie L; Hedley D; Curtin JA; Bastian BC; Springer C; Marais R
Cancer Res; 2006 Oct; 66(19):9483-91. PubMed ID: 17018604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
